Piper Jaffray raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $201.00 (from $194.00) while maintaining a Overweight rating.Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE